Back to Search
Start Over
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.
- Source :
- Inflammatory Bowel Diseases; Jan2022, Vol. 28 Issue 1, p62-69, 8p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 10780998
- Volume :
- 28
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Inflammatory Bowel Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 154595893
- Full Text :
- https://doi.org/10.1093/ibd/izab027